Evidence map›Paper›PMID 41461954›Full record

ReviewHandbook of experimental pharmacology2026

Direct Oral Anticoagulant Inhibitors: Mode of Action, Clinical Aspects.

Eman Hassan, Will Lester

Abstract readReview
PubMed Publisher
In one paragraph

Review in Handbook of experimental pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Eman HassanDepartment of Cardiovascular Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. eman.hassan@uhb.nhs.uk.ORCID https://orcid.org/0000-0002-0696-6848
Will LesterDepartment of Cardiovascular Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This chapter provides a comprehensive overview of direct oral anticoagulants (DOACs), focusing on their mechanisms of action, clinical utility, and practical considerations in anticoagulation management. DOACs have revolutionised anticoagulation by selectively targeting thrombin and activated factor X (FXa), offering improved safety, predictable pharmacokinetics, and reduced need for monitoring. The chapter covers their indications, contraindications, dosing, perioperative management, reversal, and use in special populations, including those with renal or hepatic impairment, cancer-associated thrombosis, and extreme body weights. It provides clinicians with practical guidance for the effective application of DOACs in various clinical settings.

Indexed as

AnticoagulantsBlood CoagulationFactor Xa InhibitorsAdministration, OralAnimalsHemorrhageHumansThrombosisAnticoagulantsFactor Xa InhibitorsAnticoagulation therapyAtrial fibrillationCancer-associated thrombosisDirect oral anticoagulantsDOACsExtreme body weightFactor Xa inhibitorsHepatic impairmentPerioperative managementRenal impairmentThrombin inhibitorsVenous thromboembolism

Identifiers

PMID41461954

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.